• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Allergy . Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes

tetano

Editor, Senior Moderator
Allergy


. 2021 Aug 28.
doi: 10.1111/all.15066. Online ahead of print.
Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes


Pia Gattinger[SUP] 1 [/SUP], Katarzyna Niespodziana[SUP] 1 [/SUP], Karin Stiasny[SUP] 2 [/SUP], Sabina Sahanic[SUP] 3 [/SUP], Inna Tulaeva[SUP] 1 4 [/SUP], Kristina Borochova[SUP] 1 [/SUP], Yulia Dorofeeva[SUP] 1 [/SUP], Thomas Schlederer[SUP] 1 [/SUP], Thomas Sonnweber[SUP] 3 [/SUP], Gerhard Hofer[SUP] 5 [/SUP], Renata Kiss[SUP] 6 [/SUP], Bernhard Kratzer[SUP] 7 [/SUP], Doris Trapin[SUP] 7 [/SUP], Peter A Tauber[SUP] 7 [/SUP], Arno Rottal[SUP] 7 [/SUP], Ulrike Körmöczi[SUP] 7 [/SUP], Melanie Feichter[SUP] 7 [/SUP], Milena Weber[SUP] 1 [/SUP], Margarete Focke-Tejkl[SUP] 1 8 [/SUP], Judith Löffler-Ragg[SUP] 3 [/SUP], Bernhard Mühl[SUP] 9 [/SUP], Anna Kropfmüller[SUP] 10 [/SUP], Walter Keller[SUP] 11 [/SUP], Frank Stolz[SUP] 6 [/SUP], Rainer Henning[SUP] 6 [/SUP], Ivan Tancevski[SUP] 3 [/SUP], Elisabeth Puchhammer-Stöckl[SUP] 2 [/SUP], Winfried F Pickl[SUP] 7 8 [/SUP], Rudolf Valenta[SUP] 1 8 [/SUP]



Affiliations

Abstract

Background: The determinants of successful humoral immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of critical importance for the design of effective vaccines and the evaluation of the degree of protective immunity conferred by exposure to the virus. As novel variants emerge, understanding their likelihood of suppression by population antibody repertoires has become increasingly important.
Methods: In this study we analysed the SARS-CoV-2 polyclonal antibody response in a large population of clinically well-characterized patients after mild and severe COVID-19 using a panel of microarrayed structurally folded and unfolded SARS-CoV-2 proteins, as well as sequential peptides, spanning the surface spike protein (S) and the receptor-binding domain (RBD) of the virus.
Results: S- and RBD-specific antibody responses were dominated by immunoglobulin G (IgG), mainly IgG[SUB]1[/SUB] , and directed against structurally folded S and RBD and three distinct peptide epitopes in S2. The virus-neutralization activity of patients´ sera was highly correlated with IgG antibodies specific for conformational but not sequential RBD epitopes and their ability to prevent RBD binding to its human receptor angiotensin-converting enzyme 2 (ACE2). Twenty percent of patients selectively lacked RBD-specific IgG. Only immunisation with folded, but not with unfolded RBD, induced antibodies against conformational epitopes with high virus-neutralizing activity. Conformational RBD epitopes required for protection do not seem to be altered in the currently emerging virus variants.
Conclusion: These results are fundamental for estimating the protective activity of antibody responses after natural infection or vaccination and for the design of vaccines, which can induce high levels of SARS-CoV-2-neutralizing antibodies conferring sterilizing immunity.

Keywords: COVID-19; SARS-CoV-2; conformational epitopes; protective antibodies; vaccine; virus neutralization.
 
Back
Top Bottom